Dariohealth Corp Stock Price, News & Analysis

DarioHealth Corp. (Nasdaq: DRIO) announced a new study on its digital therapeutics for Type 2 diabetes published in the Journal of Diabetes Science and Technology. The study showed a 2.0% reduction in average HbA1c values among participants using the Dario app alongside certified coaching. Other notable findings included an 18% reduction in fasting blood glucose and a 10% reduction in BMI. The research highlights the effectiveness of combining digital self-monitoring with live coaching, supporting Dario's mission to enhance diabetes management.

DarioHealth Corp. (Nasdaq: DRIO) will participate in the 18th Annual Craig-Hallum Institutional Investor Conference on June 2. CEO Erez Raphael and President Rick Anderson will host meetings with registered investors. DarioHealth is a leader in digital therapeutics, focusing on chronic condition management through AI-powered solutions. Their tools promote behavioral change and improve health outcomes, with a strong reputation in diabetes and hypertension care. For more information, visit dariohealth.com.

DarioHealth Corp. (Nasdaq: DRIO) announced the acquisition of PsyInnovations, Inc. (dba wayForward) for $30 million. This behavioral health digital platform offers AI-based screening, digital Cognitive Behavioral Therapy (CBT), and more, currently serving around 20,000 members. The acquisition is expected to be accretive to revenue in 2021 and significantly more in 2022. Dario aims to enhance its multi-condition solutions and improve member outcomes, addressing a growing behavioral health need among those with chronic conditions. The deal involves $25 million at closing and a contingent payment of up to $5 million based on future revenue thresholds.

DarioHealth Corp. (Nasdaq: DRIO) reported a strong first quarter of 2021, with revenues reaching $3.6 million, a 73% sequential increase from Q4 2020 and 116% year-over-year. Pro-forma revenues, accounting for the acquisition of Upright Technologies, would have been $4.7 million. Gross margin improved to 44.7%, up from 24.2% in Q4 2020. However, the net loss widened to $15 million, reflecting a significant rise in operating expenses totaling $15.4 million. The company holds over $81 million in cash, positioning it well for future growth while focusing on B2B2C and chronic condition market expansions.

DarioHealth Corp. (Nasdaq: DRIO) will release its Q1 2021 financial results on May 17, 2021, after market close. A conference call will be held on May 18, 2021, at 8:30 am ET, featuring CEO Erez Raphael and executives Rick Anderson and Zvi Ben-David. The call can be accessed via dial-in at 1-877-451-6152 or through a webcast. A replay will be available post-event until June 18, 2021. DarioHealth is known for its innovative digital therapeutics, particularly in diabetes and hypertension management, focusing on adaptive and personalized health solutions.

DarioHealth Corp. (NASDAQ: DRIO) announced that Rick Anderson, President and GM of North America, will speak at the Fifth International Vatican Conference from May 6-8, 2021. The event gathers global leaders to discuss advancements in health care and chronic disease management. Anderson's presentation will focus on technology's role in behavior change and health improvement, advocating for equitable access to care through digital solutions. The conference features notable speakers and promotes the #UnitedToPrevent campaign centered on health innovation.

DarioHealth Corp. (Nasdaq: DRIO) has launched a new virtual care initiative in collaboration with MediOrbis, targeting Medicare members with diabetes. This program provides convenient telehealth services and remote patient monitoring, leveraging Dario's AI-powered platform. Approximately 75,000 existing Dario members with diabetes will benefit from the initiative, which also targets a broader Medicare audience, potentially accessing millions of beneficiaries. The program is aligned with Dario's strategy to enhance user value while expanding revenue opportunities, particularly in remote patient monitoring.

DarioHealth Corp. (Nasdaq: DRIO) announced its financial results for Q4 and the full year 2020, highlighting a transition to a SaaS model and B2B2C digital therapeutics approach. Total revenues rose modestly in Q4 to $2.08 million, a 15.7% increase year-over-year. However, gross profit declined to $549,000, marking a 34.6% drop, while operating losses surged 117% to $9.1 million. The company secured key contracts and successfully raised $70 million through a private placement. Cash reserves stand at approximately $90 million, supporting future growth initiatives.

DarioHealth Corp. (NASDAQ: DRIO) will participate in the Stephens 2021 Best Ideas Conference on March 11, 2021. CEO Erez Raphael and President Rick Anderson will present virtually at 9:00 a.m. ET, with a live webcast available for replay. DarioHealth specializes in digital therapeutics, offering AI-powered solutions for chronic conditions like diabetes and hypertension. The company aims to drive behavioral change through personalized experiences and clinically proven digital tools. For more details, visit dariohealth.com.